Neuren Pharmaceuticals is an Australian biopharmaceutical company that develops and commercialises treatments for rare neurodevelopmental disorders. Its main product is trofinetide, an oral medicine for Rett syndrome, and it also works on therapies for other conditions such as Fragile X syndrome and Phelan-McDermid syndrome. The company is based in Melbourne and its customers are mainly patients, clinicians and healthcare systems in markets where its medicines are approved and sold.
The shares are listed on the Australian Securities Exchange in Australia under the code NEU, and the price on this page is in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Strong price profile
Ranks #282 of 1816 on the Australian Securities Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Australia yet.
TrendStrong
92/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average24.1%
From 52-week high-16.2%
MomentumStrong
82/100
Rising faster than most stocks on this exchange.
See the numbers →
3-month return15.4%
6-month return64.4%
12-month, skipping last month-1.5%
Stability (higher is calmer)Fair
63/100
Typical risk for this exchange.
See the numbers →
Volatility, 1 year (lower is calmer)56.7%
Worst drawdown, 1 year (smaller is calmer)-48.6%
LiquidityStrong
92/100
Trades actively.
See the numbers →
Avg daily value traded10.13M AUD
Zero-volume days0.0%
IncomeWeak
3/100
Dividend is small or irregular.
See the numbers →
Dividend yield0.8%
Years with dividends1
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Australia when fundamentals data for this market is added. All Australia stocks.
52-wk range 11.00 – 23.76Daily closes, split-adjusted
Signals
50-day average20.58
200-day average15.96
Golden/death cross (60d)Golden, 54 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.70
Technical summary
Daily
Neutral
6 bullish · 4 neutral · 6 bearish
Weekly
Strongly bullish
9 bullish · 1 neutral · 2 bearish
Monthly
Strongly bullish
6 bullish · 1 neutral · 1 bearish
Moving averages (daily)
SMA 10
19.77
Bullish
EMA 10
19.81
Bullish
SMA 20
19.99
Bearish
EMA 20
19.97
Bearish
SMA 50
20.58
Bearish
EMA 50
19.86
Bearish
SMA 100
18.52
Bullish
EMA 100
18.77
Bullish
SMA 200
15.96
Bullish
EMA 200
17.51
Bullish
Oscillators (daily)
RSI (14)
46.74
Neutral
MACD (12, 26)
-0.19
Bearish
Momentum (12)
-1.93
Bearish
Stochastic %K (14)
52.87
Neutral
Williams %R (14)
-47.13
Neutral
CCI (20)
-82.36
Neutral
Pivot points (classic, last session)
S3
18.88
S2
19.07
S1
19.44
Pivot
19.63
R1
20.00
R2
20.19
R3
20.56
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.15 AUD
Yield on today's price
0.76%
Frequency
Annual
Next ex-dividend date
Not announced
Ex-dividend date
Amount per share
0.1500
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
Prices are end-of-day closes in AUD. Educational only, not financial advice.
